title: Luteinizing hormone-releasing hormone analogue (Buserelin) treatment for central precocious puberty: a multi-centre trial.
abstract: A multi-centre open trial of Buserelin, a luteinizing hormone-releasing hormone (LHRH) analogue, was conducted in 13 children with central precocious puberty. Eleven children (eight girls and three boys), aged 3.4-10.2 years at commencement, completed the required 12 month period of treatment. Initially all patients received the drug by intranasal spray in a dose of 1200 micrograms/day, but by the end of the 12 month period two were having daily subcutaneous injections and three were receiving an increased dose intranasally. The first month of treatment was associated in one boy with increased aggression and masturbation, and in the girls with an increase in the prevalence of vaginal bleeding. Thereafter, however, both behavioural abnormalities and menstruation were suppressed. Median bone age increased significantly during the study, but without any significant change in the ratio of height age to bone age. The median predicted adult height for the group therefore did not alter significantly over the twelve months of the study. Buserelin treatment caused a reduction in the peak luteinizing hormone and follicle-stimulating hormone (FSH) responses to LHRH, mostly to prepubertal levels, and also suppressed basal FSH. In the first weeks of treatment, the girls' serum oestradiol levels rose significantly and then fell to prepubertal or early pubertal levels. A similar pattern was seen for serum testosterone levels. Serum somatomedin-C levels, however, showed little fluctuation over the course of the study. Buserelin treatment was safe and well accepted, and offers the promise of improved linear growth potential in precocious puberty.
authors.affiliation: Royal Children's Hospital, Melbourne, Victoria, Australia.
authors.forename: G A
authors.initials: GA
authors.lastname: Werther
authors.forename: G L
authors.initials: GL
authors.lastname: Warne
authors.forename: G
authors.initials: G
authors.lastname: Ennis
authors.forename: H
authors.initials: H
authors.lastname: Gold
authors.forename: M
authors.initials: M
authors.lastname: Silink
authors.forename: C T
authors.initials: CT
authors.lastname: Cowell
authors.forename: C
authors.initials: C
authors.lastname: Quigley
authors.forename: N
authors.initials: N
authors.lastname: Howard
authors.forename: G
authors.initials: G
authors.lastname: Antony
authors.forename: G C
authors.initials: GC
authors.lastname: Byrne
mesh_terms: D000280:Administration, Inhalation; D000365:Age Determination by Skeleton; D001827:Body Height; D002064:Buserelin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D015337:Multicenter Studies as Topic; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology
chemical_list: D002064:Buserelin